Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zäuner, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zäuner, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1994) 9: 619-622
© 1994 European Renal Association-European Dialysis and Transplant Association

research-article

Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial

I. Zäuner1,, J. Böhler1, N. Braun2, C. Grupp3, P. Heering4, P. Schollmeyer1 and for the Collaborative Glomerulonephritis Therapy Study Group (CGTS)

1Department of Nephrology, Universities of Freiburg Germany 2Department of Nephrology, Universities of Tübingen Germany 3Department of Nephrology, Universities of Ulm Germany 4Department of Nephrology, Universities of Düsseldorf Germany

Correspondence and offprint requests to: Correspondence and offprint requests to: Dr I. Zäuner, Medizinische Klinik IV, Universität Freiburg, Hugstetter Str. 55, 79106 Freiburg i.Br., Germany

Idiopathic membranoproliferative glomerulonephritis (MPGN) has a poor prognosis, with 90% of patients requiring dialysis treatment after 20 years regardless of therapy. Up to 34% of patients may die due to thrombotic complications or sepsis. This study investigates the influence of aspirin plus dipyridamole on proteinuria and renal function in nephrotic MPGN patients with moderately reduced glomerular nitration rate.

Eighteen patients with biopsy-proven MPGN (15 type I, 3 type II) and nephrotic syndrome were randomly assigned to receive protein restriction, anti-hypertensive therapy (control group) or in addition aspirin and dipyridamole (treatment group). Patients were prospectivly followed for a mean of 36 months.

Serum creatinine remained unchanged after 36 months compared to baseline in both groups. In the treatment group proteinuria was reduced from 8.3±1.4 to 1.6±0.7g/day (P<0.05). In control patients proteinuria decreased from 7.1±1.6 to 4.3±1.1 g/day. After 36 months proteinuria was significantly lower in the treatment group compared to control (P<0.02 Mann-Whitney rank sum test).

In conclusion, aspirin plus dipyridamole may be of value in reversing nephrotic syndrome and associated risks in patients with MPGN and moderately reduced renal function.

Keywords: idiopathic membranoproliferative glomerulonephritis; aspirin; dipyridamole


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
R. J.H. Smith, J. Alexander, P. N. Barlow, M. Botto, T. L. Cassavant, H. T. Cook, S. R. de Cordoba, G. S. Hageman, T. S. Jokiranta, W. J. Kimberling, et al.
New Approaches to the Treatment of Dense Deposit Disease
J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2447 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Jones, M. Juszczak, E. Kingdon, M. Harber, P. Sweny, and A. Burns
Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids
Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3160 - 3164.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.